Tibet Aim Pharm. (SZ:002826) Xin Lang Zheng Quan·2025-10-31 23:30Core Insights - 易明医药 is a pharmaceutical company established in December 2007, focusing on the research, production, and sales of chemical drugs and traditional Chinese medicine, with strengths in generic drugs [1] Financial Performance - In Q3 2025, 易明医药 reported revenue of 489 million yuan, ranking 81st among 110 companies in the industry, while the industry leader, 华东医药, achieved revenue of 32.664 billion yuan [2] - The company's net profit for the same period was 81.76 million yuan, placing it 55th in the industry, with the top performer, 恒瑞医药, reporting a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, 易明医药's debt-to-asset ratio was 24.24%, an increase from 22.52% year-on-year, which is below the industry average of 35.26% [3] - The company's gross profit margin for Q3 2025 was 82.15%, up from 67.05% year-on-year, exceeding the industry average of 57.17% [3] Management Compensation - The total compensation for the general manager was 681,600 yuan in 2024, a decrease of 23,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 19,400, while the average number of circulating A-shares held per shareholder increased by 9.38% to 8,968.79 [5]